{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068564","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.516084+00:00","generated_at":"2026-05-21T22:56:08.941378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC","bullets":["Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.","Net loss $26.4M ($1.03/sh) narrowed from $63.5M ($3.04/sh) Q1 2024; revenue $24.1M (non-cash royalty).","On track to cut annualized cash burn below $50M in H2 2025; final stages of collaboration for cash infusion.","BOT/BAL showed 100% pCR in dMMR CRC at higher dose; NEOASIS study responses in TNBC, sarcomas; HCC durable.","Appointed Dr. Richard Goldberg as Chief Development Officer to lead BOT/BAL regulatory engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068564","json":"https://secwatch.observer/filing/0000950170-25-068564.json","markdown":"https://secwatch.observer/filing/0000950170-25-068564.md","text":"https://secwatch.observer/filing/0000950170-25-068564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/0000950170-25-068564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/agen-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T22:56:08.941378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}